Alkermes PLC said its depression drug helped patients not responding to standard treatments, news that added more than $3 billion to the company's market value in after-hours trading.

The company said that in a late-stage trial, its ALKS 5461 treatment significantly improved depression scores in patients who had an inadequate response to standard therapies. The most commonly reported adverse events associated with the treatment were nausea, dizziness and fatigue.

Alkermes said it plans to request a meeting with the U.S. Food and Drug Administration to discuss the filing strategy for the treatment, which has a fast-track designation.

Shares of Alkermes rose 47% to $64.10 in after-hours trading. At that price, the company has a market cap of $9.7 billion, up from its valuation of $6.59 billion at the end of the regular session Thursday.

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

October 20, 2016 17:25 ET (21:25 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Alkermes Charts.
Alkermes (NASDAQ:ALKS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Alkermes Charts.